"uuid:ID","name","rationale","label","id","description","instanceType"
"0d8a4b01-a837-45b7-bf2d-f17a0c470766","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign_1","The main design for the study","StudyDesign"
